Several years after approval of anti-vascular endothelial growth factor-targeted therapy for locally advanced and metastatic clear cell renal cell carcinoma, we discovered and/or validated new clinical, biochemical, pathological, pharmacokinetic, molecular and genetic markers predictive for response and/or prognostic in metastatic clear cell renal cell carcinoma patients treated with anti-vascular endothelial growth factor-receptor-tyrosine kinase inhibitors.
(BELG J MED ONCOL 2015;9(1):35–41)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
